Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
02
03
2022
received:
23
11
2021
accepted:
12
03
2022
pubmed:
22
3
2022
medline:
22
10
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks. We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways. Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Sections du résumé
BACKGROUND AND AIMS
Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
APPROACH AND RESULTS
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
CONCLUSIONS
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Identifiants
pubmed: 35313030
doi: 10.1002/hep.32467
pmc: PMC9489820
mid: NIHMS1790833
doi:
Substances chimiques
Receptor, Insulin
EC 2.7.10.1
Protein Kinases
EC 2.7.-
Collagen
9007-34-5
Serine
452VLY9402
Discoidin Domain Receptors
EC 2.7.10.1
Threonine
2ZD004190S
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1376-1388Subventions
Organisme : NIMH NIH HHS
ID : R01 MH121102
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057598
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121797
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107487
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA177558
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA024333
Pays : United States
Informations de copyright
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Case Rep Gastroenterol. 2010 Mar 17;4(1):100-103
pubmed: 21103235
Am J Physiol Gastrointest Liver Physiol. 2018 Jun 1;314(6):G668-G676
pubmed: 29494209
Hepatology. 2022 Nov;76(5):1376-1388
pubmed: 35313030
Horm Metab Res. 1980 Nov;12(11):577-81
pubmed: 7007194
Hepatology. 1999 Jun;29(6):1743-51
pubmed: 10347117
Trends Endocrinol Metab. 2018 Mar;29(3):140-150
pubmed: 29409713
Am J Pathol. 2010 Jun;176(6):2743-52
pubmed: 20395449
Am J Physiol Regul Integr Comp Physiol. 2019 Nov 1;317(5):R733-R745
pubmed: 31483154
Matrix Biol. 2018 Aug;68-69:435-451
pubmed: 29656147
Biomolecules. 2020 Mar 02;10(3):
pubmed: 32131495
Front Pharmacol. 2020 Dec 18;11:594574
pubmed: 33390979
Ital J Gastroenterol. 1992 Feb;24(2):65-71
pubmed: 1576365
Methods Mol Med. 2005;117:237-50
pubmed: 16118456
Metabolism. 1982 Dec;31(12):1241-6
pubmed: 6755167
J Cell Mol Med. 2018 Oct;22(10):5050-5061
pubmed: 30106235
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
Dig Liver Dis. 2005 May;37(5):349-56
pubmed: 15843085
Cells. 2020 Apr 03;9(4):
pubmed: 32260126
J Biol Chem. 2014 Jun 20;289(25):17885-94
pubmed: 24817119
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Mol Cell Endocrinol. 2014 Jan 25;382(1):197-204
pubmed: 24071517
Gut. 2010 Feb;59(2):267-73
pubmed: 20176643
Trends Endocrinol Metab. 2021 Nov;32(11):862-874
pubmed: 34481731
Curr Med Sci. 2020 Jun;40(3):539-547
pubmed: 32681257
Int J Mol Sci. 2020 Dec 14;21(24):
pubmed: 33327438
Int J Mol Sci. 2020 Nov 21;21(22):
pubmed: 33233470
Trends Endocrinol Metab. 2015 Apr;26(4):212-20
pubmed: 25726384
Obesity (Silver Spring). 2014 Mar;22(3):705-12
pubmed: 23839791
J Biol Chem. 2016 Nov 25;291(48):25179-25191
pubmed: 27738106
Acta Med Okayama. 1981 Jun;35(3):155-64
pubmed: 6457506
BMC Gastroenterol. 2021 Jun 12;21(1):263
pubmed: 34118892
Dig Dis Sci. 2017 Apr;62(4):968-978
pubmed: 28194671
Cell Signal. 2018 Sep;49:105-115
pubmed: 29902522
Int J Environ Res Public Health. 2021 Feb 12;18(4):
pubmed: 33673200
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):195-206
pubmed: 21497738
J Clin Endocrinol Metab. 1982 Sep;55(3):524-30
pubmed: 6284782
Clin Sci (Lond). 2017 Jun 7;131(12):1301-1315
pubmed: 28468951
J Exp Med. 2020 Feb 13;217(3):e20190103
pubmed: 32997468
Matrix Biol. 2014 Feb;34:185-92
pubmed: 24361528
Am J Physiol Endocrinol Metab. 2017 Apr 1;312(4):E244-E252
pubmed: 28096081
Nutr Metab (Lond). 2019 Oct 11;16:69
pubmed: 31632452
Klin Wochenschr. 1987 Sep 15;65(18):873-8
pubmed: 3312788
PLoS One. 2007 Nov 07;2(11):e1134
pubmed: 17987120
Nat Rev Endocrinol. 2021 Aug;17(8):484-495
pubmed: 34131333
Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118474
pubmed: 30954571